HTS 시장 규모는 2024년에 232억 6,000만 달러로 평가되었고, 2024년부터 2031년까지 연평균 복합 성장률(CAGR) 7.75%로 성장할 전망이며, 2031년에는 400억 4,000만 달러에 이를 것으로 예측됩니다.
고처리량 스크리닝(HTS)은 창약 및 기타 연구 분야에서 특정 표적 및 조건에 대해 수천 개의 화합물, 생물학적 샘플 및 유전 물질을 신속하게 시험하는 데 사용되는 기술입니다.
이 기술은 자동화 기술을 이용하여 수많은 분석을 동시에 수행하여 잠재적인 약물 후보 및 생물학적 활성을 효율적으로 확인할 수 있습니다. HTS는 일반적으로 로봇 공학, 전용 소프트웨어 및 고급 검출 시스템을 사용하여 샘플을 신속하게 처리하고 분석합니다.
용도로서, HTS는 주로 제약 연구에서 효능, 독성 또는 특정 생물학적 표적과의 상호 작용에 대한 화합물의 대규모 라이브러리를 스크리닝함으로써 유망한 약물 후보를 확인하는 데에 사용됩니다.
또한 유전체학와 단백질체학에서도 유전자의 기능, 단백질의 상호작용, 질병 메커니즘의 연구에 이용되고 있습니다. 또한 HTS는 화학 물질이 다양한 생물 시스템에 미치는 영향을 평가하고 새로운 농업 화합물을 발견하기 위해 환경 과학 및 농업 과학에서도 사용됩니다.
의약품 수요 증가 : 신규 및 효과적인 의약품에 대한 요구가 증가함에 따라 방대한 화합물 라이브러리에서 잠재적인 의약품 후보를 효율적으로 확인하는 고처리량 스크리닝(HTS)의 채택을 뒷받침하고 있습니다. 미국 식품의약국(FDA)에 따르면 2023년 신약 개발에 걸리는 평균 비용은 26억 달러로 평가되었고, 최초 발견부터 시장 승인까지의 기간은 10-15년입니다. 이 높은 비용과 긴 시간축은 HTS와 같은 보다 효율적인 스크리닝 기법의 필요성을 증가시키고 있습니다.
자동화 기술의 진보 : 로봇 공학과 자동화 기술의 끊임없는 개선으로 HTS 프로세스의 효율성과 속도가 향상되어 대규모 연구에 보다 사용하기 쉽고 효과적입니다. 미국 국립표준기술연구소(NIST)는 2023년 실험실 자동화의 진보로 HTS 시스템의 평균 처리량이 지난 5년간 35% 향상되었다고 보고했습니다.
개인화된 의료에 대한 관심 증가 : 개인화된 의료로의 전환에 따라 복잡한 생물학적 데이터를 분석하고 개별 환자에 맞는 치료 표적을 확인하기 위한 높은 처리량 기술이 필요합니다. 맞춤형 의료 연합(Personalized Medicine Coalition)의 보고에 따르면, 2023년에 FDA가 승인한 신약의 25%는 맞춤형 의료로 분류되어 2022년의 20%에서 증가했습니다.
연구개발에 대한 투자 증가 : 생물의학 연구 및 의약품 연구개발에 대한 자금과 투자 증가는 HTS 능력의 확대를 지원하고 보다 종합적이고 다양한 스크리닝을 가능하게 합니다. 미국 연구제약공업협회(PhRMA)의 보고에 따르면 회원기업의 2023년 연구개발 투자액은 추정 1,023억 달러로 2022년부터 7.5% 증가했습니다.
생명공학과 유전체학 확대 : 생명공학과 유전체학 연구를 확대하려면 대규모 데이터세트를 처리하고 치료 개발의 핵심인 유전적, 분자적 표적을 파악하기 위한 고급 스크리닝 기술이 필요합니다. 예를 들어, 2024년 3월, Ginkgo Bioworks는 유전체 데이터 분석을 통합한 새로운 HTS 플랫폼을 발표하여 치료 응용의 가능성이 있는 유전자 변이를 하루에 10만 개 이상 스크리닝할 수 있게 되었습니다.
주요 과제
복잡한 데이터 관리 : HTS는 엄청난 양의 데이터를 생성하므로 관리, 분석 및 효과적인 해석에 어려움이 동반됩니다. 이 데이터를 처리하려면 고급 소프트웨어와 숙련된 인력이 필요하며 리소스가 많이 필요합니다.
기술적 한계와 신뢰성 문제 : HTS 기술은 분석의 신뢰성, 감도, 특이성 문제에 직면할 수 있습니다. 기술적 한계는 위양성과 위음성을 유발할 수 있으며, 스크리닝 프로세스의 정확성과 효율성에 영향을 미칩니다.
통합 과제 : HTS 시스템을 기존 실험실 워크플로우 및 데이터 인프라와 통합하는 것은 복잡하고 시간이 많이 소요됩니다. 호환성 문제와 광범위한 유효성 검증의 필요성은 원활한 배포를 방해할 수 있습니다.
규제 및 컴플라이언스 장애물 : 엄격한 규제 요건과 업계 표준을 준수할 필요성은 HTS 프로세스를 복잡하게 만듭니다. 이러한 규제에 대한 컴플라이언스를 확보하는 것은 운영상의 과제와 비용에 박차를 가합니다.
높은 초기 비용 : 고급 HTS 장비를 구입하고 유지하는 데 필요한 엄청난 자본은 스크리닝 분석의 개발 및 검증과 관련된 비용과 함께 소규모 실험실 및 조직에 있어서 엄청난 수 있습니다.
주요 동향
인공지능과 머신러닝의 통합 : HTS에 AI와 머신러닝을 통합하면 데이터 분석과 해석이 향상됩니다. 이러한 기술은 스크리닝 결과의 정확성을 향상시키고 패턴 및 히트 가능성을 보다 효율적으로 파악하고 데이터 처리에 소요되는 시간을 단축합니다. 2023년 미국립위생연구소(NIH)의 보고서에 따르면, 의약품 및 HTS에서 AI와 머신러닝의 이용은 2020년에서 2023년까지 35% 증가했습니다. 이 통합은 의약 스크리닝 캠페인에서 첫 번째 히트 화합물 식별에 필요한 시간을 40% 단축했습니다.
어세이 기술의 발전 : 보다 민감하고 특이적인 어세이의 개발과 같은 어세이 기술의 혁신은 HTS의 능력을 확대하고 있습니다. 분석법의 개발에 의해 생물학적 표적을 보다 상세하고 신뢰성 높은 방법으로 스크리닝할 수 있게 되어, 보다 효과적인 창약 및 약제 개발에 공헌하고 있습니다. 프로메가 코퍼레이션은 2023년 12월에 단백질-단백질 상호작용 연구를 위해 10배의 고감도를 제공하는 강화된 생물발광 리포터 어세이를 출시했습니다.
자동화 및 로보틱스 채택 확대 : HTS 시스템에서의 자동화 및 로보틱스 증가는 처리량과 효율성 향상을 추진하고 있습니다. 자동화된 플랫폼은 스크리닝 프로세스를 간소화하고, 인적 실수를 줄이고, 보다 많은 양의 샘플을 처리할 수 있게 함으로써 보다 빠르고 비용 효율적인 연구와 발견을 촉진합니다. High Res Biosolutions는 주요 제약 회사와 제휴하여 2024년 1월 발표한 적응 스크리닝을 위한 AI 구동 로봇 시스템을 개발했습니다.
High Throughput Screening Market size was valued at USD 23.26 Billion in 2024 and is projected to reach USD 40.04 Billion by 2031, growing at a CAGR of 7.75% from 2024 to 2031.
High Throughput Screening (HTS) is a method used in drug discovery and other research fields to rapidly test thousands of compounds, biological samples, or genetic materials against specific targets or conditions.
This technique utilizes automated technologies to conduct a large number of assays simultaneously, enabling the efficient identification of potential drug candidates or biological activities. HTS typically involves robotics, specialized software, and sophisticated detection systems to process and analyze samples quickly.
In terms of application, HTS is predominantly used in pharmaceutical research to identify promising drug candidates by screening large libraries of compounds for their efficacy, toxicity, or interactions with specific biological targets.
It is also employed in genomics and proteomics to study gene function, protein interactions, and disease mechanisms. Additionally, HTS is utilized in environmental and agricultural sciences to assess the impact of chemicals on various biological systems and to discover new agricultural compounds.
The key market dynamics that are shaping the global high throughput screening market include:
Rising Drug Discovery Demands: The increasing need for new and effective pharmaceuticals drives the adoption of High Throughput Screening (HTS) to efficiently identify potential drug candidates from vast compound libraries. According to the U.S. Food and Drug Administration (FDA), as of 2023, the average cost to develop a new drug was estimated at USD 2.6 Billion, with a timeline of 10-15 years from initial discovery to market approval. This high cost and long timeline drive the need for more efficient screening methods like HTS.
Advancements in Automation Technologies: Continuous improvements in robotics and automation technologies enhance the efficiency and speed of HTS processes, making them more accessible and effective for large-scale research. The National Institute of Standards and Technology (NIST) reported in 2023 that advancements in laboratory automation have increased the average throughput of HTS systems by 35% over the past five years.
Growing Focus on Personalized Medicine: The shift towards personalized medicine necessitates high-throughput methods to analyze complex biological data and identify tailored therapeutic targets for individual patients. The Personalized Medicine Coalition reported that 25% of all new drugs approved by the FDA in 2023 were classified as personalized medicines, up from 20% in 2022.
Increased Investment in Research and Development: Growing funding and investment in biomedical research and pharmaceutical R&D support the expansion of HTS capabilities, enabling more comprehensive and diverse screening efforts. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that its member companies invested an estimated $102.3 billion in R&D in 2023, up 7.5% from 2022.
Expansion of Biotechnology and Genomics: The rise in biotechnology and genomics research requires advanced screening technologies to handle large datasets and identify key genetic and molecular targets for therapeutic development. For instance, in March 2024, Ginkgo Bioworks unveiled a new HTS platform integrating genomic data analysis, capable of screening over 100,000 genetic variants per day for potential therapeutic applications.
Key Challenges:
Complex Data Management: HTS generates vast amounts of data that can be challenging to manage, analyze, and interpret effectively. Handling this data requires sophisticated software and skilled personnel, which can be resource-intensive.
Technical Limitations and Reliability Issues: HTS technologies may face issues with assay reliability, sensitivity, and specificity. Technical limitations can lead to false positives or negatives, impacting the accuracy and efficiency of the screening process.
Integration Challenges: Integrating HTS systems with existing laboratory workflows and data infrastructure can be complex and time-consuming. Compatibility issues and the need for extensive validation can hinder seamless implementation.
Regulatory and Compliance Hurdles: The need to adhere to stringent regulatory requirements and industry standards can complicate the HTS process. Ensuring compliance with these regulations adds to the operational challenges and costs.
High Initial Costs: The significant capital required for purchasing and maintaining advanced HTS equipment, along with the costs associated with developing and validating screening assays, can be prohibitive for smaller laboratories and organizations.
Key Trends
Integration of Artificial Intelligence and Machine Learning: The incorporation of AI and machine learning into HTS is enhancing data analysis and interpretation. These technologies improve the accuracy of screening results, identify patterns and potential hits more efficiently, and reduce the time required for data processing. According to a report by the National Institutes of Health (NIH) in 2023, the use of AI and machine learning in drug discovery and HTS increased by 35% from 2020 to 2023. This integration has led to a 40% reduction in the time required for initial hit identification in drug screening campaigns.
Advancements in Assay Technologies: Innovations in assay technologies, such as the development of more sensitive and specific assays, are expanding the capabilities of HTS. Enhanced assay methods allow for more detailed and reliable screening of biological targets, contributing to more effective drug discovery and development. Promega Corporation launched an enhanced bioluminescent reporter assay in December 2023, offering 10 times higher sensitivity for protein-protein interaction studies.
Growing Adoption of Automation and Robotics: Increased automation and robotics in HTS systems are driving higher throughput and efficiency. Automated platforms streamline the screening process, reduce human error, and enable the handling of larger sample volumes, facilitating faster and more cost-effective research and discovery. HighRes Biosolutions partnered with a leading pharmaceutical company to develop an AI-driven robotic system for adaptive screening, announced in January 2024.
Here is a more detailed regional analysis of the global high throughput screening market:
North America
North America dominating the global high throughput screening (HTS) market, driven by its advanced research infrastructure and strong focus on innovation in pharmaceuticals and biotechnology. The United States and Canada are at the forefront of adopting and integrating HTS technologies, leveraging their well-established R&D ecosystem and significant investments in cutting-edge research.
Several key factors contribute to North America's dominance in the HTS market. The region's robust pharmaceutical and biotechnology industries drive demand for efficient drug discovery and development processes, supported by substantial funding and a strong pipeline of research projects. Additionally, North America's well-developed infrastructure, including leading research institutions and pharmaceutical companies, further fuels the growth of HTS technologies.
In North America, notable trends include the increasing integration of artificial intelligence and machine learning into HTS processes to enhance data analysis and predictive capabilities. There is also a growing emphasis on personalized medicine, leading to more sophisticated and tailored screening assays. Furthermore, advancements in automation and robotics are streamlining HTS workflows, boosting efficiency, and enabling higher throughput in drug discovery and development.
Asia Pacific
Asia-Pacific, with China as a key player, is witnessing rapid growth in the High Throughput Screening (HTS) market. The region's expanding biotechnology and pharmaceutical sectors are driving the adoption of advanced HTS technologies, positioning Asia-Pacific as a significant and fast-growing market for screening solutions.
The rapid growth of the HTS market in Asia-Pacific is driven by several factors. In China, substantial investments in pharmaceutical research and biotechnology are fueling demand for efficient drug discovery tools. Additionally, the region's expanding research infrastructure, increasing focus on personalized medicine, and supportive government policies contribute to the accelerated adoption of HTS technologies.
Key trends in the Asia-Pacific HTS market include the rising integration of advanced automation and robotics to enhance screening efficiency and throughput. There is also a growing emphasis on developing and utilizing novel screening assays to support complex drug discovery processes. Furthermore, increasing collaborations between regional research institutions and global pharmaceutical companies are driving innovation and expanding the reach of HTS technologies across the region.
The Global High Throughput Screening Market is Segmented on the basis of Technology, Application, Product & Service, And Geography.
Based on Technology, the Global High Throughput Screening Market is bifurcated into Cell-Based Assays, Lab-on-a-Chip (LOC), Label-Free Technology, Ultra-High-Throughput Screening (UHTS). The cell-based assay technology is projected to lead the market during the forecast. This dominance is primarily due to the ability of this technology to generate multiple biologically relevant data. Also, the assessing compound attributes is another factor projected to enhance the application of cell-based assay.
Based on Application, the Global High Throughput Screening Market is bifurcated into Drug Discovery, Target Identification, Primary Screening, and Toxicology. In the high throughput screening (HTS) market, cell-based assays are currently dominating due to their broad applicability in drug discovery and biological research. These assays are essential for evaluating cellular responses to various compounds and are widely used across pharmaceutical and biotechnology industries. Conversely, Label-Free Technology is the rapidly growing segment, driven by its ability to provide real-time, non-invasive measurements without the need for labels or dyes. This technology offers advantages such as reduced assay complexity and improved accuracy, contributing to its increasing adoption and rapid growth in the HTS market.
Based on Product & Service, the Global High Throughput Screening Market is bifurcated into Instruments, Consumables, Services, and Software. In the high throughput screening (HTS) market, instruments are the dominating segment, as they form the backbone of HTS systems, enabling the automation and high-throughput capabilities necessary for large-scale screening processes. The demand for sophisticated and high-performance HTS instruments drives this segment's leading position. Meanwhile, software is the rapidly growing segment, fueled by advancements in data analytics, machine learning, and artificial intelligence. Enhanced software solutions for data management and analysis are becoming increasingly vital for interpreting complex screening results and improving overall HTS efficiency, contributing to its swift growth.
Based on Geography, the Global High Throughput Screening Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In the high throughput screening (HTS) market, North America is the dominating region, driven by its advanced research infrastructure, strong pharmaceutical and biotechnology sectors, and significant investments in cutting-edge HTS technologies. The region's established market presence and extensive R&D activities contribute to its leading position. Conversely, Asia Pacific is the rapidly growing region, with China and other countries in the area experiencing substantial growth due to increasing investments in research and development, expanding pharmaceutical industries, and the adoption of advanced HTS technologies. This region's rapid industrialization and focus on innovation are fueling its swift expansion in the HTS market.
The "Global High Throughput Screening Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Rheon Automatic Machinery, GEA Group, Middleby Corporation, Marel, Bettcher Industries, Formax, Inc., Magurit Gefrierschneider GmbH, Minerva Omega Group, Metalbud NOWICKI.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.